Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00190736 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 440
- Enrollment target
NCT00190736 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 440 participants.
The verdict
NCT00190736, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 440 participants
- Enrollment target
Study Summary
A study to compare the effect of once-daily atomoxetine versus placebo in treating symptoms of ADHD in adults for up to 6 months.
Interventions
- DRUG placebo
- DRUG Atomoxetine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2004-09 |
| Est. Completion | 2006-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00190736
The ClinicalTrials.gov registry entry for NCT00190736 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 440 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00190736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00190736 about?
NCT00190736 is a clinical study titled "Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)". A study to compare the effect of once-daily atomoxetine versus placebo in treating symptoms of ADHD in adults for up to 6 months.
What is the current status of trial NCT00190736?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 440 participants. The study started on 2004-09. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00190736?
The interventions under investigation include: placebo (DRUG), Atomoxetine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00190736?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.